02-06-2026 17:06 via drugs.com

ASCO: Teclistamab Improves Survival in Relapsed, Refractory Multiple Myeloma

TUESDAY, June 2, 2026 -- For patients with relapsed or refractory multiple myeloma, teclistamab monotherapy significantly improves progression-free and overall survival, according to a study published online May 29 in the New England Journal of...
Read more »

Pharmaceutical Industry news



High Prevalence of Clinical Obesity Seen Even With Normal BMI
FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection
ASCO: Lower Incidence of Breast Cancer Seen With GLP-1 Receptor Agonist Exposure
ASCO: First-Line Sunvozertinib Beats Chemo for Advanced NSCLC
Patients From Most Rural Counties Have Worse Epilepsy Outcomes
2024 Saw Parkinson Disease Death Rate of 72 Per 100,000 Adults Aged 65 and Older
Resistance Training Tied to Lower Risk for Death Across Causes
Gut Microbial, Metabolomic Alterations Persist After Adenoma Resection
Cumulative Attrition for Surgeons 9.7 Percent Over Eight Years
Microbially Derived Metabolites in Urine May Help Identify Autism in Children
Monthly News Roundup - May 2026
Influenza Vaccine Effective for Children Aged 2 to 5 Years
Tezepelumab Reduces Need for Oral Corticosteroids in Adults With Asthma
ASCO: Modest Accuracy Seen for Existing Breast Cancer Risk Prediction Models
Desktop versie